Compare Nippon India Pharma Fund vs SBI Healthcare Opportunities Fund
Nippon India Pharma Fund
EquitySectoral-Pharma
SBI Healthcare Opportunities Fund
EquitySectoral-Pharma
Risk
Very High
Very High
Rating
2.0
5.0
Min SIP Amount
₹100
₹500
Expense Ratio
1.85
1.99
NAV
₹604.31
₹563.66
Fund Started
10 May 2004
04 Jun 1999
Fund Size
₹9166.40 Cr
₹5870.00 Cr
Exit Load
Exit load of 1% if redeemed within 1 month.
Exit load of 0.50% if redeemed within 15 days
1 Year
4.66%
11.56%
3 Year
15.38%
20.58%
5 Year
11.45%
15.68%
Equity
97.31%
95.53%
Cash
2.67%
4.41%
Top 10 Holdings
Name | Assets |
|---|---|
Sun Pharmaceutical Industries Ltd. | 11.71% |
Divi's Laboratories Ltd. | 7.10% |
Lupin Ltd. | 6.17% |
Cipla Ltd. | 6.01% |
Dr. Reddy's Laboratories Ltd. | 5.45% |
Apollo Hospitals Enterprise Ltd. | 4.89% |
Mankind Pharma Ltd. | 4.38% |
Sai Life Sciences Ltd. | 3.92% |
Ajanta Pharma Ltd. | 3.61% |
Glaxosmithkline Pharmaceuticals Ltd. | 3.11% |
Name | Assets |
|---|---|
Sun Pharmaceutical Industries Ltd. | 11.14% |
Divi's Laboratories Ltd. | 7.91% |
Acutaas Chemicals Ltd. | 5.03% |
Apollo Hospitals Enterprise Ltd. | 4.45% |
Torrent Pharmaceuticals Ltd. | 4.42% |
Cipla Ltd. | 4.40% |
Laurus Labs Ltd. | 4.05% |
Max Healthcare Institute Ltd. | 3.80% |
Aurobindo Pharma Ltd. | 3.42% |
Aster DM Quality Care Ltd. | 3.21% |
Name
-
-
Start Date
-
-
Description
The scheme seeks to generate consistent returns by investing in equity / equity related or fixed income securities of pharma and other associated companies.
The scheme seeks to provide the investors with the opportunity of long-term capital appreciation by investing in a diversified portfolio of equity and equity related securities in Healthcare space.
Launch Date
10 May 2004
04 Jun 1999
